Elsevier

Brain Research Bulletin

Volume 55, Issue 5, 15 July 2001, Pages 631-640
Brain Research Bulletin

Striatal ionotropic glutamate receptor expression in schizophrenia, bipolar disorder, and major depressive disorder

https://doi.org/10.1016/S0361-9230(01)00523-8Get rights and content

Abstract

Abnormalities of the ionotropic glutamate receptors (N-methyl-D-aspartate, α-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid [AMPA], and kainate) have been reported in the brain in schizophrenia, although in complex, region-specific patterns. While limbic cortex and medial temporal lobe structures have been most often studied in psychiatric illnesses, glutamate receptors are expressed in other brain regions associated with limbic circuitry, especially the striatum. In this study, we have determined striatal ionotropic glutamate receptor expression in brains from persons with schizophrenia, bipolar disorder, major depression, and a comparison group, using samples from the Stanley Foundation Neuropathology Consortium. We have determined the expression of these receptors at multiple levels of gene expression by using both in situ hybridization and receptor autoradiography. The expression of nearly all of these molecules was not different in these psychiatric conditions. The only significant changes noted were NR2D and gluR1 transcripts, and [3H]AMPA binding. This is the first comprehensive study of striatal ionotropic glutamate receptor expression in schizophrenia and affective disorders, and suggests that there are minimal changes in these receptors in this region of the brain in these illnesses.

Introduction

A growing body of evidence has implicated glutamatergic abnormalities in major psychiatric conditions, particularly schizophrenia. Glutamate exerts its effects as a neurotransmitter through four distinct receptor families (Fig. 1). The ionotropic receptors constitute three of the four families, and exist as N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA), and kainate subtypes. Each of the ionotropic receptors is composed of multimeric associations of subunits that form ligand-gated ion channels. On the other hand, the metabotropic glutamate receptors are seven transmembrane domain, G-protein coupled receptors [23].

The ionotropic receptors are composed of family-specific subunits [23]. The AMPA receptor subunits are derived from four different genes, gluR1-gluR4. Kainate receptors are composed of subunits derived from genes for the low affinity gluR5-gluR7 and high affinity KA1-KA2 subunits. Subunits associated with both the AMPA and kainate receptors exist in multiple forms due to alternative splicing and editing of their respective transcripts [23]. Accordingly, there is the potential for heterogeneity in both AMPA and kainate receptors, based on subunit composition and transcriptional modification of individual subunits. Subunit composition is physiologically relevant for both AMPA and kainate receptors, as unique pharmacological properties are associated with specific subunit complements in the final receptors. For example, gluR2-containing AMPA receptors have decreased calcium ion flux, which decreases the electrophysiological activity of these receptors 5, 15, 22, 29, 56.

The NMDA receptor subunits are encoded by five genes, NR1 and NR2A-NR2D [23]. NR1 can be expressed as one of eight isoforms, due to the alternative splicing of exons 5, 21, and 22 9, 23, 42. The pharmacological regulation of the NMDA receptor depends on the unique combination of binding sites [23]. There is a primary site for the binding of glutamate. A separate glycine binding site must also be occupied before glutamate can activate the ion channel. Modulatory binding sites for polyamines, pH, and zinc have also been identified. There is a site for magnesium, which blocks the channel at physiological concentrations. This blockade is voltage dependent; partial depolarization of the cell membrane will extrude magnesium. Therefore, presynaptic glutamate release and postsynaptic pre-depolarization are both required for NMDA receptor activity. Finally, there is a site within the ion channel itself associated with the binding of uncompetitive antagonists of the NMDA receptor, such as PCP, ketamine, and MK-801. These antagonists are use-dependent, i.e., the ion channel must be opened for these compounds to bind to the receptor, so there must be cooperativity between multiple sites for occupancy of uncompetitive antagonists. Similar to the AMPA and kainate receptors, subunit composition is physiologically relevant: the NMDA binding sites are associated with different subunits, and their affinities can vary depending on subunit composition 3, 14, 18, 35, 41, 50.

Several lines of evidence have implicated glutamatergic dysfunction in schizophrenia, particularly associated with the NMDA receptor. For example, uncompetitive inhibitors of the MK-801 sensitive intrachannel site can cause psychosis in non-psychiatrically ill individuals 33, 37, and worsen psychotic symptoms in persons with schizophrenia 27, 34, 36. Agonists of the glycine co-agonist site of the NMDA receptor have been found to ameliorate negative psychotic symptoms in schizophrenia 7, 16, 21, 28, 51. These observations suggest that schizophrenia may be associated with decreased NMDA receptor activity 6, 27. Although the NMDA receptor is the subtype of glutamate receptor usually implicated in schizophrenia, the other ionotropic glutamate receptors also may be abnormal in this illness. A growing literature suggests abnormal expression of all three families of ionotropic glutamate receptors in the brain in schizophrenia [39], although in complex and regionally specific patterns. While prefrontal and cingulate cortex, and medial temporal lobe structures have been most often studied in psychiatric illnesses, these receptors are expressed in other brain regions associated with the limbic circuitry felt to be disturbed in psychiatric illnesses, including the striatum and thalamus.

In the present study, we have examined the expression of the NMDA, AMPA, and kainate receptors in the striatum in persons with schizophrenia, as well as bipolar disorder, major depression, and a comparison group. We have approached this study by examining the expression of these receptors at different levels of gene expression, by determining the expression of the transcripts encoding each of the subunits, as well as multiple binding sites associated with these receptors. This is the first comprehensive study of the expression of the ionotropic glutamate receptors in the striatum in these psychiatric disorders, and adds to the growing literature that suggests heterogeneity of abnormal expression of these receptors in the brain in schizophrenia and other psychiatric illnesses.

Section snippets

Subjects

Sixty subjects from the Stanley Foundation Neuropathology Consortium were studied, comprised of four groups of 15 subjects each with diagnoses of schizophrenia, bipolar disorder, major depressive disorder, and a comparison group. A detailed description of this collection has been published recently [57]; summary characteristics of the subjects are shown in Table 1. Cryostat-sectioned (14 um) slides from the fresh frozen half of these brains were provided to us by the Stanley Foundation

NMDA receptor expression

The transcripts encoding the ionotropic glutamate receptor subunits and multiple binding sites were readily identifiable in the striatal subregions studied (Fig. 2). All five of the NMDA subunits were detected, although NR1, NR2A, and NR2B were by far the most abundant. The four ligands used to label the specific binding sites associated with the NMDA complex were also visualized throughout the striatum. There were few significant differences in the expression of the molecules that are

Discussion

Past studies on the expression of the ionotropic glutamate receptors in the brain in psychiatric illnesses have almost exclusively focused on schizophrenia, have concentrated on cortical and medial temporal lobe structures, and have generally revealed complex, region- and receptor-specific abnormalities. Relatively few studies have focused on the expression of these receptors in subcortical limbic structures. Our results reveal that there are no differences in the expression of the ionotropic

Acknowledgements

This work was supported by MH53327 to Dr. Meador-Woodruff. Postmortem brains were donated by the Stanley Foundation Brain Consortium courtesy of Drs. Llewellyn B. Bigelow, Juraj Cervenak, Mary M. Herman, Thomas M. Hyde, Joel E. Kleinman, Jose D. Paltan, Robert M. Post, E. Fuller Torrey, Maree J. Webster, and Robert H. Yolken.

References (58)

  • D.J Healy et al.

    AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics

    Neuropsychopharmacology

    (1998)
  • H.M Ibrahim et al.

    Nucleus-specific expression of ionotropic glutamate receptor subunit mRNAs and binding sites in primate thalamus

    Mol Brain Res.

    (2000)
  • P Jonas et al.

    Differences in Ca2+ permeability of AMPA-type glutamate receptor channels in neocortical neurons caused by differential GluR-B subunit expression

    Neuron

    (1994)
  • R Kerwin et al.

    Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem

    Neuroscience

    (1990)
  • R.W Kerwin et al.

    Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia

    Lancet

    (1988)
  • A.C Lahti et al.

    Subanesthetic doses of ketamine stimulate psychosis in schizophrenia

    Neuropsychopharmacology

    (1995)
  • A.K Malhotra et al.

    NMDA receptor function and human cognitionThe effects of ketamine in healthy volunteers

    Neuropsychopharmacology

    (1996)
  • J.H Meador-Woodruff et al.

    Abnormal kainate receptor expression in prefrontal cortex in schizophrenia

    Neuropsychopharmacology.

    (2001)
  • J.H Meador-Woodruff et al.

    Glutamate receptor expression in schizophrenic brain

    Brain Res. Rev.

    (2000)
  • T Nishikawa et al.

    Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia

    Neurosci. Lett.

    (1983)
  • T Ohnuma et al.

    Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia

    Brain Res. Mol. Brain Res.

    (1998)
  • R.H Porter et al.

    Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia

    Brain Res.

    (1997)
  • S.M Richardson-Burns et al.

    Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus

    Biol. Psychiatry

    (2000)
  • J.M Rodriguez-Paz et al.

    Block of the N-methyl-D-aspartate receptor by phencyclidine-like drugs is influenced by alternative splicing

    Neurosci. Lett.

    (1995)
  • E.F Torrey et al.

    The Stanley Foundation brain collection and Neuropathology Consortium

    Schizophr. Res.

    (2000)
  • S Akbarian et al.

    Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics

    J. Neurosci.

    (1996)
  • M.I Aparicio-Legarza et al.

    Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients

    Neurosci. Lett.

    (1998)
  • M Carlsson et al.

    SchizophreniaA subcortical neurotransmitter imbalance syndrome?

    Schizophr. Bull.

    (1990)
  • N.G Cascella et al.

    D-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophreniaAn open-label study

    J. Neural Transm.

    (1994)
  • Cited by (136)

    View all citing articles on Scopus
    View full text